Posted by Michael Wonder on 17 May 2022
Valneva receives notice of European Commission’s intent to terminate COVID-19 vaccine purchase agreement
16 May 2022 - Valneva today announced that it has received a notice from the European Commission of intent to terminate the advance purchase agreement for Valneva’s inactivated whole virus COVID-19 vaccine candidate VLA2001.
The advance purchase agreement provides the European Commission with a right to terminate the APA if VLA2001 had not received a marketing authorisation from the EMA by 30 April 2022.
